Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NNMT | P40261 | 1/20 | 0.37 |
| ▸ | LOX | P28300 | 1/20 | 0.36 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.36 |
| ▸ | GABRP | O00591 | 1/20 | 0.35 |
| ▸ | GABRD | O14764 | 1/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.35 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.35 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.35 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.35 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.35 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.35 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.35 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.35 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.35 |
| ▸ | GABRE | P78334 | 1/20 | 0.35 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.35 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.35 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.35 |
| ▸ | GABRQ | Q9UN88 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30954879 | 0.86 | NNMT (0.37) | NNMT | |
| SCHEMBL15710933 | 0.83 | NNMT (0.37) | NNMTGABRPGABRDGABRA1GABRB1 | |
| SCHEMBL676690 | 0.80 | NNMT (0.40) | NNMTLOXLOXL2GABRPGABRD | |
| SCHEMBL31124303 | 0.80 | NNMT (0.40) | NNMTLOXLOXL2GABRPGABRD | |
| SCHEMBL29907269 | 0.77 | NNMT (0.50) | NNMTGABRPGABRDGABRA1GABRB1 | |
| SCHEMBL28015248 | 0.77 | NPC1 (0.42) | NNMTGABRPGABRDGABRA1GABRB1 | |
| SCHEMBL3573917 | 0.77 | AXL (0.42) | NNMTGABRPGABRDGABRA1GABRB1 | |
| SCHEMBL18659548 | 0.77 | NNMT (0.46) | NNMTLOXLOXL2GABRPGABRD | |
| SCHEMBL364584 | 0.77 | NNMT (0.50) | NNMTGABRPGABRDGABRA1GABRB1 | |
| SCHEMBL31449583 | 0.76 | OXTR (0.41) | GABRPGABRDGABRA1GABRB1GABRG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 150 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122036680-A | Anti-fibrotic pyridones | 英特穆恩公司 | 2026-05-15 | — | — | CN | disclosed |
| US-12595255-B2 | Heteroaryl-substituted imidazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2026-04-07 | — | — | US | disclosed |
| EP-4678641-A1 | QUINOLINONE COMPOUND AND NAPHTHYRIDINONE COMPOUND AND USE THEREOF | Shanghai Helioson Pharmaceutical Co., Ltd. (CN) | 2026-01-14 | — | — | EP | disclosed |
| EP-4635949-A1 | SUBSTITUTED TETRAHYDROCYCLOPENTYL[C]PYRROLE DERIVATIVE, PREPARATION METHOD, INTERMEDIATE AND USE THEREOF | Jiangsu NHWA Pharmaceutical Co., Ltd (CN) | 2025-10-22 | — | — | EP | disclosed |
| US-12421228-B2 | Naphthyridine derivatives as PRC2 inhibitors | Mirati Therapeutics, Inc. (US) | 2025-09-23 | — | — | US | disclosed |
| US-20250282787-A1 | SUBSTITUTED IMIDAZO[1,2-c]PYRIMIDINES AS PRC2 INHIBITORS | Mirati Therapeutics, Inc. | 2025-09-11 | — | — | US | disclosed |
| EP-4134364-B1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2025-07-30 | — | — | EP | disclosed |
| US-12371435-B2 | Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors | Mirati Therapeutics, Inc. (US) | 2025-07-29 | — | — | US | disclosed |
| US-20250179082-A1 | IMIDAZO[1,2-C]PYRIMIDINE DERIVATIVES AS PRC2 INHIBITORS FOR TREATING CANCER | Mirati Therapeutics, Inc. | 2025-06-05 | — | — | US | disclosed |
| WO-2025096751-A1 | MACROCYCLIC INHIBITORS OF ATP CITRATE LYASE | ESPERION THERAPEUTICS, INC. (US) | 2025-05-08 | — | — | WO | disclosed |
| CN-102165961-A | Bactericide composition and method of controlling plant disease | ISHIHARA SANGYO KAISHA | 2011-08-31 | — | — | CN | disclosed |
| EP-2338335-A1 | Preparation of fungicidal benzoylpyridine derivatives | ISHIHARA SANGYO KAISHA, LTD. (JP) | 2011-06-29 | — | — | EP | disclosed |
| CN-101822253-A | The method of control of microbicide compositions and plant disease | ISHIHARA SANGYO KAISHA | 2010-09-08 | — | — | CN | disclosed |
| CN-100581362-C | Bactericide composition and method for controlling plant diseases | ISHIHARA SANGYO KAISHA | 2010-01-20 | — | — | CN | disclosed |
| US-20090247763-A1 | FUNGICIDAL COMPOSITION AND METHOD FOR CONTROLLING PLANT DISEASES | ISHIHARA SANGYO KAISHA, LTD. (JP) | 2009-10-01 | — | — | US | disclosed |
| CN-101215260-A | Method for preparing benzoylpyridine derivatices and salt thereof | ISHIHARA SANGYO KAISHA (JP) | 2008-07-09 | — | — | CN | disclosed |
| CN-101199274-A | Bactericide composition and method for controlling plant disease | ISHIHARA SANGYO KAISHA (JP) | 2008-06-18 | — | — | CN | disclosed |
| CN-1874680-A | bactericide composition and method for controlling plant diseases | ISHIHARA SANGYO KAISHA (JP) | 2006-12-06 | — | — | CN | disclosed |
| US-20060194849-A1 | Fungicidal composition and method for controlling plant diseases | ISHIHARA SANGYO KAISHA, LTD. (JP) | 2006-08-31 | — | — | US | disclosed |
| EP-1679003-A1 | BACTERICIDE COMPOSITION AND METHOD OF CONTROLLING PLANT DISEASE | ISHIHARA SANGYO KAISHA, LTD. (JP) | 2006-07-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247763-A1 | FUNGICIDAL COMPOSITION AND METHOD FOR CONTROLLING PLANT DISEASES | CBR3, CBR1, CNPY2 | NNMT 1513/4885LOX 756/4885LOXL2 1864/4885 |
| US-12371435-B2 | Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors | EZH2, BMI1, SUZ12 | NNMT 1251/4885LOX 3548/4885LOXL2 3867/4885 |
| US-20250282787-A1 | SUBSTITUTED IMIDAZO[1,2-c]PYRIMIDINES AS PRC2 INHIBITORS | EZH2, BMI1, SUZ12 | NNMT 609/4885LOX 2753/4885LOXL2 3004/4885 |
| US-20250179082-A1 | IMIDAZO[1,2-C]PYRIMIDINE DERIVATIVES AS PRC2 INHIBITORS FOR TREATING CANCER | BMI1, EZH2, SUZ12 | NNMT 647/4885LOX 2086/4885LOXL2 2477/4885 |
| US-20060194849-A1 | Fungicidal composition and method for controlling plant diseases | CBR3, CNPY2, PAH | NNMT 1528/4885LOX 756/4885LOXL2 1916/4885 |
| US-12595255-B2 | Heteroaryl-substituted imidazole derivatives | CLIC1, CYP2B6, CYP2D6 | NNMT 4285/4885LOX 1283/4885LOXL2 3045/4885 |
| US-12421228-B2 | Naphthyridine derivatives as PRC2 inhibitors | BMI1, EZH2, SUZ12 | NNMT 388/4885LOX 1843/4885LOXL2 2113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.